Australia today has embarked on a local vaccine manufacturing operation developed by Oxford University with around 30 million doses to be produced.
While still undergoing the third phase clinical trial, the vaccine, which is also part of AstraZeneca's efforts, is considered one of the most potentially effective vaccines.
Victoria-based biotechnology firm CSL, responsible for vaccine production, is expected to release the vaccine in the first half of 2021 if the test proves successful.
The action is taken maybe a little risky. However, CSL's Chief Scientific Officer, Andrew Nash hoped that this effort would bear fruit, in line with the clinical trial process which was then available for community use.
Each person will receive two doses of the vaccine. This means that the effectiveness of the vaccine is available to 15 million people.
However, the vaccine will not be distributed for use as long as the expansion process is not evaluated and approved by the Australian authorities, the Therapeutic Goods Administration (TGA).
CSL also produced several other doses of the COVID-19 vaccine, developed by the University of Queensland (UQ), now available for the next clinical trial, Phase 2b / 3.
For now, they are still waiting for confirmation and survey information for the Phase 1 clinical trial.
